Showing results (611-620 of 640) with videos related to

Sort By:
Pageof 64
Annals of Gastroenterology|March 23, 2026
Efficacy of current therapeutic strategies for immune checkpoint inhibitor-related esophagitisCarolina Colli Cruz, Maria Julia M N Santos, Sharada Wali, et al.
Contemporary Clinical Trials|February 7, 2018
Promoting Successful Weight Loss in Primary Care in Louisiana (PROPEL): Rationale, design and baseline characteristicsPeter T Katzmarzyk, Corby K Martin, Robert L Newton, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 9, 2026
Independent Testing to Accelerate the Development of Lateral Flow Assays for Influenza A, Influenza B and SARS-COV-2Anuradha Rao, Laura Johnson, Leda Bassit, et al.
The New England Journal of Medicine|September 3, 2020
Weight Loss in Underserved Patients - A Cluster-Randomized TrialPeter T Katzmarzyk, Corby K Martin, Robert L Newton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2022
Treatment of Metastatic Colorectal Cancer: ASCO GuidelineVan K Morris, Erin B Kennedy, Nancy N Baxter, et al.
The New England Journal of Medicine|October 12, 2017
Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in LiberiaStephen B Kennedy, Fatorma Bolay, Mark Kieh, et al.
Annals of Gastroenterology|January 30, 2026
Immune-mediated diarrhea and colitis with normal biochemical, endoscopic and histologic findings: a retrospective studyMalek Shatila, Sharada Wali, Carolina Colli Cruz, et al.
Microbiology Spectrum|October 27, 2021
Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein MicroarrayDavid Camerini, Arlo Z Randall, Krista Trappl-Kimmons, et al.
Trials|January 24, 2021
Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countriesMoses Badio, Edouard Lhomme, Mark Kieh, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profilesC C Chan, S Boyce, C Brideau, et al.
Pageof 64